Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding how an AAV gene-therapy startup finances multi-million-dollar trials and mitigates overexpression risks can feel impossible. Taysha Gene Therapies鈥� SEC disclosures span technical manufacturing details, RMAT negotiations and complex stock-based compensation鈥攃ritical points easily missed when you skim 200-page reports.
Stock Titan鈥檚 AI steps in when you search for phrases like 鈥淭aysha Gene Therapies quarterly earnings report 10-Q filing鈥� or 鈥淭aysha Gene Therapies insider trading Form 4 transactions.鈥� Our engine reads every newly posted document on EDGAR, then delivers plain-English answers. Whether you need the Taysha Gene Therapies annual report 10-K simplified, a snapshot of Taysha Gene Therapies executive stock transactions Form 4, or an alert when an 8-K material event is filed, we surface the essentials. The platform even tags sections investors ask about most鈥攃ash runway, AAV manufacturing capacity, and clinical safety data鈥攕o you can act before markets adjust.
Use cases go beyond quick summaries. Analysts rely on our real-time feed of Taysha Gene Therapies Form 4 insider transactions real-time to spot buying ahead of trial readouts. Portfolio managers compare segments through Taysha Gene Therapies earnings report filing analysis, while governance teams review the Taysha Gene Therapies proxy statement executive compensation for alignment with shareholder interests. If you have ever Googled 鈥渦nderstanding Taysha Gene Therapies SEC documents with AI,鈥� this page is your answer: comprehensive filings, live updates and AI-powered clarity, all in one place.
The Schedule 13G filed on 27 June 2025 discloses that The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have acquired beneficial ownership of 12,748,968 shares of Taysha Gene Therapies, Inc. (TSHA) common stock. The position represents 5.1 % of TSHA鈥檚 outstanding shares, crossing the 5 % reporting threshold under Section 13(d) of the Securities Exchange Act.
All voting and dispositive authority over the shares is reported as shared; neither entity claims sole authority. The filing is on Schedule 13G, indicating a passive investment rather than an effort to influence control, as confirmed by the Item 10 certification.
Goldman Sachs & Co. LLC is classified as a broker-dealer, other organization, and investment adviser, while The Goldman Sachs Group, Inc. is identified as a holding company/control person. No additional group members or activist exhibits are included.
The disclosure confirms meaningful institutional ownership by a globally recognized financial institution, potentially improving share liquidity and lending credibility to TSHA. However, because it is a passive filing, it does not imply forthcoming strategic or operational changes at the issuer.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
What is the primary focus of Taysha Gene Therapies, Inc.?
Which technology platform does TSHA use for its gene therapies?
How does Taysha differentiate itself in the biotechnology market?
What are some key product candidates in TSHA's pipeline?
What regulatory designations has TSHA achieved for its lead candidate?
Who are the likely stakeholders or customers for TSHA's therapies?
How do strategic partnerships enhance TSHA's capabilities?
What role does TSHA's experienced management team play?
